Pliant Therapeutics Inc (PLRX)
Pliant Therapeutics, Inc. is a clinical-stage biopharmaceutical company listed on NASDAQ under the ticker PLRX. The company is focused on discovering and developing integrin-based therapies, with an emphasis on treatments for solid tumors. Its lead candidate, PLN-101095, is an oral small-molecule dual inhibitor of avß8 and avß1 integrins that is being evaluated in Phase 1a/1b testing for solid tumors. Pliant Therapeutics also maintains a drug discovery platform built around a proprietary library of more than 15,000 integrin-binding molecules, supporting its work in integrin-based target-mediated drug delivery. Incorporated in 2015, the company is headquartered in South San Francisco, California.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-PLRX
|
$1.48
|
35.6% Upside
|
Undervalued
|
$2.50
|
129.4% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 10, 2026
|
-0.6x
|
0.4x
|
—
|
66.255 M
|
-74.615 M
|
30.3%
|
92.2%
|
-4.7
|
—
|
87.3%
|
